Overview of Inflammatory and Coagulation Markers in Elderly Patients with COVID-19: Retrospective Analysis of Laboratory Results
Authors:
- Corina PopazuCPCorina Popazu
- Aurelia RomilaARAurelia Romila
- Marius PetreaMPMarius Petrea
- Robert Marius GrosuRGRobert Marius Grosu
- Alina-Maria LescaiALAlina-Maria Lescai
- Adriana Liliana VladAVAdriana Liliana Vlad
- Violeta Diana OpreaVOVioleta Diana Oprea
- Alexia Anastasia Ștefania BaltăABAlexia Anastasia Ștefania Baltă
Open Access
Abstract
Background: Elderly patients with COVID-19 often exhibit a complex interplay between hypercoagulability and coagulopathy, key factors in determining the risk of severe complications and mortality. This study aimed to analyze coagulation and inflammatory markers to identify critical predictors of adverse outcomes in this vulnerable population. Material and Methods: The retrospective study was conducted on a sample of 1429 elderly patients (≥60 years) diagnosed with COVID-19, hospitalized in “Sf. Ap. Andrei” St. Apostle Andrew’s County Emergency Hospital in various wards between March 2020 and August 2022. Data were collected from medical records and included inflammatory markers (C-reactive protein, procalcitonin, ESR) and coagulation markers (prothrombin time, INR, fibrinogen, D-dimer). The SPSS 2.0 statistical software was used to conduct the study. Results:Coagulation markers: Prothrombin activity averaged 74.22%, below normal levels, indicating a heightened bleeding risk, while fibrinogen levels were significantly elevated (mean: 531.69 mg/dL), reflecting hypercoagulability. Prolonged prothrombin time (mean: 17.28 s) and elevated INR (International normalized ratio) (mean: 1.51) were associated with increased mortality, emphasizing their role in risk stratification. Elevated D-dimer levels (mean: 2.75 mg/L) further highlighted thromboembolic risks. Inflammatory markers: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) showed marked elevations (mean CRP: 92.09 mg/L, mean ESR: 58.47 mm/h), correlating with heightened systemic inflammation and poor outcomes. Bacterial infections: Elevated procalcitonin (mean: 1.98 ng/mL) suggested secondary bacterial infections, particularly in mechanically ventilated patients, significantly worsening prognosis. Conclusions: The duality of hypercoagulability and coagulopathy in elderly COVID-19 patients underscores the importance of consistently monitoring coagulation markers such as prothrombin time, INR, D-dimer, and fibrinogen. Simultaneously, elevated inflammatory markers and secondary bacterial infections require prompt therapeutic interventions. This study highlights the critical need for personalized management strategies to mitigate complications and reduce mortality in this high-risk population.Keywords
This publication has 18 references indexed in Scilit:
- Development of a Model for Predicting Mortality Among Patients Hospitalized with COVID-19 During Their Stay in a Clinical CentreJournal of Clinical Medicine, 2024
- Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort studyThe Lancet Microbe, 2024
- Correlation Between Serum Procalcitonin Levels and 28-Day Mortality in Patients with Surgical Sepsis and Septic ShockChirurgia, 2023
- COVID-19 hemodynamic and thrombotic effect on the eye microcirculation after hospitalization: A quantitative case-control studyClinical Hemorheology and Microcirculation, 2022
- Skin capillary alterations in patients with acute SarsCoV2 infectionJournal Of Hypertension, 2022
- Arterial and venous thrombosis in coronavirus 2019 disease (Covid-19): relationship with mortalityInternal and Emergency Medicine, 2021
- COVID-19 and its implications for thrombosis and anticoagulationBlood, 2020
- High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort studyIntensive Care Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and reviewResearch and Practice in Thrombosis and Haemostasis, 2020